$15.09 Million in Sales Expected for Orthopediatrics Corp (KIDS) This Quarter

Equities research analysts predict that Orthopediatrics Corp (NASDAQ:KIDS) will report $15.09 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Orthopediatrics’ earnings, with the highest sales estimate coming in at $15.10 million and the lowest estimate coming in at $15.07 million. Orthopediatrics reported sales of $12.38 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 21.9%. The business is expected to issue its next earnings results on Wednesday, November 14th.

According to Zacks, analysts expect that Orthopediatrics will report full year sales of $56.48 million for the current year, with estimates ranging from $56.40 million to $56.60 million. For the next fiscal year, analysts forecast that the business will post sales of $68.69 million, with estimates ranging from $67.96 million to $69.80 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Orthopediatrics.

Orthopediatrics (NASDAQ:KIDS) last announced its quarterly earnings data on Thursday, August 9th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.07). Orthopediatrics had a negative net margin of 61.99% and a negative return on equity of 192.23%. The firm had revenue of $15.10 million during the quarter, compared to analysts’ expectations of $14.27 million. Orthopediatrics’s quarterly revenue was up 28.0% compared to the same quarter last year.

KIDS has been the subject of a number of analyst reports. Zacks Investment Research lowered shares of Orthopediatrics from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 14th. BidaskClub raised shares of Orthopediatrics from a “hold” rating to a “buy” rating in a research note on Tuesday, October 2nd. Piper Jaffray Companies increased their target price on shares of Orthopediatrics from $24.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, July 5th. William Blair reaffirmed an “outperform” rating on shares of Orthopediatrics in a research note on Wednesday, June 27th. Finally, ValuEngine raised shares of Orthopediatrics from a “hold” rating to a “buy” rating in a research note on Thursday, August 2nd. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Orthopediatrics has an average rating of “Buy” and a consensus target price of $29.25.

In other Orthopediatrics news, Director Kevin Unger sold 1,000 shares of the stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $33.22, for a total transaction of $33,220.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Daniel J. Gerritzen sold 9,525 shares of the stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $33.73, for a total transaction of $321,278.25. The disclosure for this sale can be found here. Company insiders own 46.10% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Sei Investments Co. purchased a new position in shares of Orthopediatrics in the second quarter valued at approximately $126,000. Millennium Management LLC purchased a new position in shares of Orthopediatrics in the first quarter valued at approximately $172,000. Stifel Financial Corp purchased a new position in shares of Orthopediatrics in the first quarter valued at approximately $196,000. Indiana Trust & Investment Management CO purchased a new position in shares of Orthopediatrics in the third quarter valued at approximately $248,000. Finally, Paradigm Capital Management Inc. NY purchased a new position in shares of Orthopediatrics in the second quarter valued at approximately $280,000. 40.16% of the stock is owned by institutional investors.

Shares of KIDS opened at $32.76 on Friday. The company has a quick ratio of 3.61, a current ratio of 5.98 and a debt-to-equity ratio of 0.60. Orthopediatrics has a 12-month low of $14.00 and a 12-month high of $39.81. The stock has a market capitalization of $468.64 million and a P/E ratio of -5.74.

Orthopediatrics Company Profile

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, locking cannulated blades, locking proximal femurs, spica tables, response spine systems, and pediguards; bandloc, a sub-laminar banding system; and sports medicine and other products, such as anterior cruciate ligament and medial patellofemoral ligament systems.

Featured Article: Return on Investment (ROI)

Get a free copy of the Zacks research report on Orthopediatrics (KIDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Orthopediatrics (NASDAQ:KIDS)

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply